A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions
Phase of Trial: Phase IV
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs Conestat alfa (Primary) ; Immunoglobulins
- Indications Common variable immunodeficiency
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2019 Last checked against ClinicalTrials.gov: US National Institutes of Health
- 06 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Mar 2020.
- 06 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.